Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma

Phase 2 Recruiting 780 enrolled Chiesi Farmaceutici S.p.A.

RandomizedCrossoverQuadruple-blindTreatment

Summary

This study will compare an asthma inhaler that uses a new climate friendly alternative propellant to an asthma inhaler with an existing propellant. We want to make sure both versions of the inhaler work the same way for people with mild to moderate asthma.

Timeline

Start: 2025-12-17
Primary completion: 2027-06-03
Completion: 2027-06-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Formoterol	Other / unclassified	6 ug	Inhaled
Subject	Glycopyrronium	Unknown	12.5 ug	Inhaled
Subject	beclomethasone dipropionate	Other / unclassified	100 ug	Inhaled

Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma

Summary

Timeline

Drugs

Indications